<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Causes and pathophysiology of Cushing syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Causes and pathophysiology of Cushing syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Causes and pathophysiology of Cushing syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynnette K Nieman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            André Lacroix, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of Cushing syndrome involves three steps: suspecting it on the basis of the patient's symptoms and signs, documenting the presence of hypercortisolism, and determining its cause. The last step requires an understanding of the causes and pathophysiology of the different types of Cushing syndrome; these will be reviewed here  (
         <a class="graphic graphic_figure graphicRef112079" href="/z/d/graphic/112079.html" rel="external">
          figure 1
         </a>
         ). The clinical manifestations, diagnosis, and treatment of Cushing syndrome are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/156.html" rel="external">
          "Establishing the cause of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/174.html" rel="external">
          "Overview of the treatment of Cushing syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cushing syndrome may be either corticotropin (ACTH) dependent or independent  (
         <a class="graphic graphic_table graphicRef50582" href="/z/d/graphic/50582.html" rel="external">
          table 1
         </a>
         ). Approximately 80 percent of endogenous Cushing syndrome cases are ACTH dependent, and approximately 20 percent are ACTH independent  (
         <a class="graphic graphic_figure graphicRef112079" href="/z/d/graphic/112079.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Chronic hypercortisolism inhibits both hypothalamic corticotropin-releasing hormone (CRH) and vasopressin secretion as well as ACTH secretion by normal pituitary corticotrophs [
         <a href="#rid2">
          2
         </a>
         ]. Among all patients presenting with Cushing syndrome, the most common cause is iatrogenic Cushing due to exogenous administration of glucocorticoids. The second most common form overall is Cushing disease (pituitary hypersecretion of ACTH) [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Iatrogenic or factitious'
         </a>
         below and
         <a class="local">
          'Cushing disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H409895007">
         <span class="h1">
          PSEUDO-CUSHING SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypercortisolism can occur in several disorders other than Cushing syndrome [
         <a href="#rid1">
          1,4
         </a>
         ]. When such patients present with clinical features consistent with Cushing syndrome, they may also be referred to as having physiologic hypercortisolism or pseudo-Cushing syndrome [
         <a href="#rid5">
          5
         </a>
         ]. Clinically, patients with these physiologic forms of hypercortisolism seldom have the cutaneous (ie, easy bruising, thinning, and friability) or muscle (ie, proximal muscle atrophy and weakness) signs of Cushing syndrome [
         <a href="#rid6">
          6
         </a>
         ]. However, these conditions/disorders should be excluded when evaluating patients for Cushing syndrome. (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome", section on 'Exclude physiologic hypercortisolism'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          ACTH-DEPENDENT CUSHING SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         The causes of ACTH-dependent Cushing syndrome are associated with bilateral adrenocortical hyperplasia; their relative frequency is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cushing disease (pituitary hypersecretion of ACTH) – 65 to 70 percent of all Cushing syndrome (see
         <a class="local">
          'Cushing disease'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ectopic secretion of ACTH by nonpituitary tumors – 10 to 15 percent (see
         <a class="local">
          'Ectopic ACTH syndrome'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ectopic secretion of CRH by nonhypothalamic tumors causing pituitary hypersecretion of ACTH – Less than 1 percent (see
         <a class="local">
          'Ectopic CRH syndrome'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Iatrogenic or factitious Cushing syndrome due to administration of exogenous ACTH (not glucocorticoids) – Less than 1 percent
        </p>
        <p>
        </p>
        <p>
         The hallmark biochemical feature of ACTH-dependent Cushing syndrome is a normal or elevated ACTH level, which reflects tumoral secretion. The tumor secretion of ACTH causes bilateral adrenocortical hyperplasia and hyperfunction [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Cushing disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Almost all patients with Cushing disease have a pituitary adenoma, although the tumor is often not demonstrable by imaging; rare patients have diffuse corticotroph hyperplasia even in the absence of ectopic corticotropin-releasing hormone (CRH) secretion. The tumors are usually microadenomas; only approximately 5 to 10 percent are macroadenomas. Patients with macroadenomas are more likely to have supranormal plasma ACTH concentrations than are those with microadenomas (83 versus 45 percent), and the concentrations are less likely to fall with high doses of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         [
         <a href="#rid8">
          8,9
         </a>
         ]. A smaller proportion of those with macroadenomas respond to CRH stimulation (65 versus 84 percent); however, in all of those features, there is considerable overlap between patients with microadenomas and macroadenomas [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/156.html" rel="external">
          "Establishing the cause of Cushing syndrome"
         </a>
         .)
        </p>
        <p>
         The amplitude and duration, but not the frequency, of ACTH secretory episodes are increased in Cushing disease [
         <a href="#rid10">
          10-15
         </a>
         ], and the normal ACTH circadian rhythm is usually lost  (
         <a class="graphic graphic_figure graphicRef54316" href="/z/d/graphic/54316.html" rel="external">
          figure 2
         </a>
         ). There is loss of tight synchrony between ACTH and cortisol secretory dynamics, perhaps reflecting the fact that ACTH secretion by the adenoma is not subject to hypothalamic regulation, because of suppressed CRH, and is relatively resistant to direct glucocorticoid inhibition [
         <a href="#rid16">
          16
         </a>
         ]. The increased plasma ACTH concentrations, acting alone or in concert with other growth factors [
         <a href="#rid17">
          17-20
         </a>
         ], cause bilateral adrenocortical hyperplasia and hypersecretion of cortisol  (
         <a class="graphic graphic_figure graphicRef112079" href="/z/d/graphic/112079.html" rel="external">
          figure 1
         </a>
         ). Consequently, the normal circadian rhythm in cortisol secretion is also lost  (
         <a class="graphic graphic_figure graphicRef60086" href="/z/d/graphic/60086.html" rel="external">
          figure 3
         </a>
         ). Awakening plasma ACTH and serum cortisol concentrations may be normal, but pre-bedtime concentrations are high. Salivary cortisol concentrations reflect those of serum free cortisol (see
         <a class="medical medical_review" href="/z/d/html/161.html" rel="external">
          "Measurement of cortisol in serum and saliva"
         </a>
         ). The loss of the nocturnal nadir in serum and salivary cortisol is used to document the presence of Cushing syndrome.
        </p>
        <p>
         The increased cortisol secretion is reflected by increased urinary excretion of cortisol. ACTH secretion is increased more than that of cortisol, suggesting that the adrenal cortex is relatively unresponsive to excess ACTH [
         <a href="#rid15">
          15
         </a>
         ]. ACTH receptor (MC2R) levels are relatively decreased in the adrenocortical hyperplasia tissues of patients with Cushing disease [
         <a href="#rid21">
          21,22
         </a>
         ]. The relative activity of the enzymes involved in cortisol biosynthesis does not change, and therefore, the production and excretion of cortisol precursors are increased proportionately.
        </p>
        <p>
         The corticotroph adenoma cells respond to decreases in serum cortisol concentrations by increasing ACTH secretion and to increases in serum cortisol concentrations (or other glucocorticoids such as
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ) by decreasing ACTH secretion. However, quantitatively, the cells are relatively resistant to negative feedback inhibition by glucocorticoids. In effect, the tumor cells function at a higher than normal set point for cortisol feedback inhibition [
         <a href="#rid23">
          23
         </a>
         ]. This characteristic is clinically important because it permits the use of dexamethasone suppression to distinguish between pituitary and ectopic ACTH secretion; the latter is usually more resistant to glucocorticoid negative feedback. (See
         <a class="medical medical_review" href="/z/d/html/156.html" rel="external">
          "Establishing the cause of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/160.html" rel="external">
          "Dexamethasone suppression tests"
         </a>
         .)
        </p>
        <p>
         The mechanism for the resistance of corticotroph adenoma cells to glucocorticoid negative feedback inhibition is unclear.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The resistance to glucocorticoids may, in some cases, reflect abnormalities in the glucocorticoid receptor. In one report, a somatic frame-shift mutation of the glucocorticoid type 2 receptor was found in the tumor in one of four patients with Nelson syndrome [
         <a href="#rid24">
          24
         </a>
         ]. In another study, the tumors of 6 of 22 patients with Cushing disease showed loss of heterozygosity for one of five polymorphisms at the glucocorticoid receptor type 1 gene [
         <a href="#rid25">
          25
         </a>
         ]. Loss of heterozygosity was not detected in other types of pituitary adenomas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal expression of 11-beta-hydroxysteroid dehydrogenase isoenzyme 2 (11-beta-HSD-2), which converts cortisol to cortisone in ACTH-secreting adenoma cells, is a second possible mechanism for insensitivity to glucocorticoid feedback [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study found deficient nuclear expression of one or two proteins, Brg1 and histone deacetylase 2 (HDAC2), in 17 of 36 human corticotroph adenomas  (
         <a class="graphic graphic_figure graphicRef112079" href="/z/d/graphic/112079.html" rel="external">
          figure 1
         </a>
         ). Decreased nuclear localization of these proteins, which are involved in repression of the proopiomelanocortin (
         <em>
          POMC
         </em>
         ) gene, may account for resistance to glucocorticoid feedback in a subset of patients with Cushing disease [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The corticotroph adenomas that occur in approximately 2 percent of patients with multiple endocrine neoplasia type 1 (MEN 1) syndrome occur at the same age but tend to be larger and more resistant to glucocorticoid negative feedback than sporadic corticotroph adenomas [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
         As the adrenal glands become increasingly hyperplastic, they secrete proportionately more cortisol in response to a given increment in plasma ACTH. This response serves to restrain ACTH secretion, even to the point of "autosuppression." This phenomenon is especially pronounced in patients with Cushing disease-induced severe bilateral macronodular adrenal hyperplasia [
         <a href="#rid30">
          30-34
         </a>
         ], in whom plasma ACTH concentrations may not exceed 15 pg/mL (3 pmol/L). Such patients may be thought erroneously to have ACTH-independent Cushing syndrome, but their ACTH levels can increase following administration of CRH [
         <a href="#rid35">
          35
         </a>
         ]. However, no case of Cushing disease has been documented to progress to fully ACTH-independent Cushing syndrome.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Ectopic ACTH syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Except in some patients with benign neuroendocrine ("carcinoid") tumors, usually bronchial in origin [
         <a href="#rid36">
          36-38
         </a>
         ], ACTH secretion from malignant ectopic sources (such as from oat-cell carcinoma) is not inhibited by cortisol,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , or other glucocorticoids. In rare patients, glucocorticoids increase tumor secretion of ACTH [
         <a href="#rid39">
          39
         </a>
         ]. In general, tumors causing the ectopic ACTH syndrome tend to secrete a disproportionately greater proportion of POMC precursors, and these may be their major product. As in Cushing disease, salivary cortisol concentrations reflect those of serum free cortisol and urinary excretion of cortisol and its precursors is increased proportionately.
        </p>
        <p>
         Tumors of a wide variety of tissues, usually carcinomas rather than sarcomas or lymphomas, have been associated with the ectopic ACTH syndrome; however, Ewing sarcoma has been reported in children [
         <a href="#rid40">
          40
         </a>
         ]. Most cases are caused by neuroendocrine tumors of the lung, pancreas, or thymus [
         <a href="#rid7">
          7,41,42
         </a>
         ]. Small-cell carcinomas of the lung are probably the most common cause of biochemical hypercortisolism; often, this is not apparent clinically. Intrathoracic tumors (pulmonary and thymic carcinoids and rare multiple pulmonary tumorlets) represent the majority of patients presenting with Cushingoid features [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Inappropriate repression or expression of certain genes, presumably similar to those in normal pituitary corticotropes, causes these tumors to secrete ACTH and other POMC-derived peptides  (
         <a class="graphic graphic_figure graphicRef112079" href="/z/d/graphic/112079.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Disease-specific use of two other
         <em>
          POMC
         </em>
         promoter regions due to enhanced e2F-1 transcription, or demethylation of a region of the gene, account for
         <em>
          POMC
         </em>
         expression in some ectopic ACTH tumors [
         <a href="#rid45">
          45,46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Ectopic CRH syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the ectopic corticotropin-releasing hormone (CRH) syndrome, CRH secretion by the tumor causes hyperplasia and hypersecretion of the pituitary corticotrophs, resulting sequentially in ACTH hypersecretion, cortisol hypersecretion, and bilateral adrenal hyperplasia [
         <a href="#rid47">
          47
         </a>
         ]. In some of these patients, pituitary ACTH secretion can be inhibited by
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         [
         <a href="#rid47">
          47
         </a>
         ]. However, many of these tumors also secrete ACTH, which is not inhibited by dexamethasone [
         <a href="#rid48">
          48-52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          ACTH-INDEPENDENT CUSHING SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         The causes of ACTH-independent Cushing syndrome are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Iatrogenic or factitious Cushing syndrome, which is by far the most common cause, as noted above. (See
         <a class="local">
          'Iatrogenic or factitious'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adrenocortical adenomas and carcinomas – 18 to 20 percent. (See
         <a class="local">
          'Primary adrenocortical hyperfunction'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary pigmented nodular adrenocortical disease (PPNAD), also called bilateral adrenal micronodular hyperplasia – Less than 1 percent. (See
         <a class="local">
          'Primary pigmented nodular adrenocortical disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bilateral macronodular adrenal hyperplasia (BMAH) – Less than 1 percent; this disorder must be distinguished from macronodular hyperplasia in Cushing disease in which plasma ACTH concentrations are not suppressed [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="local">
          'Bilateral macronodular adrenal hyperplasia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Primary adrenocortical hyperfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         In Cushing syndrome due to primary adrenocortical disease (eg, adrenocortical tumor, micronodular dysplasia, or ACTH-independent macronodular hyperplasia), increased cortisol secretion suppresses both corticotropin-releasing hormone (CRH) and ACTH secretion, as it does in normal subjects and those with ACTH-dependent Cushing syndrome. The normal pituitary corticotrophs atrophy, as do the normal zonae fasciculata and reticularis of the adrenal glands.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adrenal adenomas that cause Cushing syndrome produce cortisol very efficiently. As ACTH is suppressed, serum dehydroepiandrosterone sulfate (DHEAS) concentrations and urinary excretion of DHEAS are usually low relative to urinary cortisol excretion or may be normal. However, occasional adrenal adenomas produce relatively large amounts of androgen due to an increase in the 17,20-lyase activity of CYP17 (P450c17, 17-alpha-hydroxylase) [
         <a href="#rid54">
          54
         </a>
         ]. Levels of CYP21A2 (P450c21, 21-hydroxylase), CYP17, and CYP11A1 (P450scc, cholesterol side-chain cleavage enzyme, cholesterol desmolase) mRNA are normal in cortisol-producing adenomas and 60 to 80 percent of normal in carcinomas, roughly proportional to their steroidogenic activities [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By contrast, adrenal carcinomas are frequently inefficient in terms of steroidogenesis. Since the efficiency per cell in converting cholesterol to cortisol is low but cell mass is very large, their production of cortisol precursors (eg, urinary 17-KS and serum and urinary DHEAS) is disproportionately higher. Even in patients with adrenal carcinomas who presumably do not produce excess steroids, more sensitive methods such as gas chromatography-mass spectrometry (GC-MS) identify increased urinary metabolites of several steroids and precursors of androgens (pregnanediol, pregnanetriol, androsterone, etiocholanolone) or glucocorticoids (17-hydroxyprogesterone, tetrahydro-11-deoxycortisol, cortisol, 6-hydroxy cortisol, tetrahydrocortisol, and alpha-cortol) [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/137.html" rel="external">
          "Clinical presentation and evaluation of adrenocortical tumors", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low serum aldosterone concentrations but normal or high serum or urinary concentrations of aldosterone precursors (ie, deoxycorticosterone, 18-hydroxydeoxycorticosterone, corticosterone, and 18-hydroxycorticosterone, tetrahydro-11-deoxycorticosterone [THDOC and 5-alpha THDOC]) are found in most adrenal carcinomas but not in adrenal adenomas [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Most adrenocortical tumors are monoclonal, suggesting that they result from accumulated genetic abnormalities, such as activation of proto-oncogenes and inactivation of tumor suppressor genes. The association of adrenal cancer with familial syndromes suggests specific gene abnormalities. In addition, a high proportion of adrenal tumors, mostly adenomas, causing Cushing syndrome have receptors for and are responsive to agonists such as gastric inhibitory polypeptide (GIP), vasopressin, beta-adrenergic agents, serotonin, luteinizing hormone/chorionic gonadotropin, and perhaps leptin or interleukin 1. These disorders are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/137.html" rel="external">
          "Clinical presentation and evaluation of adrenocortical tumors", section on 'Adrenocortical carcinoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/148.html" rel="external">
          "Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia", section on 'Aberrant hormone receptors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Primary pigmented nodular adrenocortical disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are both sporadic and familial forms of primary pigmented nodular adrenocortical disease (PPNAD), also called bilateral adrenal micronodular hyperplasia [
         <a href="#rid58">
          58
         </a>
         ]. The familial form, Carney syndrome or complex, is an autosomal dominant disorder characterized by two major types of findings: pigmented lentigines and blue nevi on the face, neck, and trunk, including the lips, conjunctivae, and sclerae; and multiple neoplasms, both endocrine (testicular Sertoli cells and occasionally adrenal, pituitary, or thyroid) and nonendocrine (cutaneous, mammary, atrial myxomas, and psammomatous melanotic schwannomas)  (
         <a class="graphic graphic_figure graphicRef112079" href="/z/d/graphic/112079.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/152.html" rel="external">
          "Cushing syndrome due to primary pigmented nodular adrenocortical disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">
          "Anatomy and pathology of testicular tumors", section on 'Sex cord-stromal tumors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Bilateral macronodular adrenal hyperplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         This syndrome is associated with adrenal glands that weigh from 24 to 500 g or more and contain multiple nonpigmented nodules greater than 5 mm in diameter. The nodules appear to be typical benign adrenal nodules, but the internodular cortex may be hypertrophic, rather than atrophic [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Bilateral macronodular adrenal hyperplasia (BMAH) is associated with three potential pathogenetic pathways involving ligand receptors,
         <em>
          ARMC5
         </em>
         mutations, and intra-adrenal production of ACTH [
         <a href="#rid60">
          60
         </a>
         ]. Overexpression of eutopic receptors, inappropriate expression of ectopic receptors, or coupling of eutopic receptors to steroidogenic signaling pathways; in the majority of patients, increases in cortisol secretion are mediated by overexpression of receptors for either vasopressin, serotonin, beta-adrenergic agonists, luteinizing hormone/chorionic gonadotropin, GIP, or perhaps glucagon or leptin [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/148.html" rel="external">
          "Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia"
         </a>
         .)
        </p>
        <p>
         Most initial cases of BMAH appeared to be sporadic, but there are now several reports of familial cases of BMAH whose presentation suggests autosomal dominant transmission of an
         <em>
          ARMC5
         </em>
         mutation. The relationship between inappropriate receptor expression and the
         <em>
          ARMC5
         </em>
         mutation is not clear. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/148.html" rel="external">
          "Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         There are occasional reports that are difficult to reconcile with current understanding of the pathophysiology of ACTH-independent primary adrenal disease. As an example, adrenal adenomas have been described in association with bilateral nodular hyperplasia [
         <a href="#rid61">
          61
         </a>
         ], as has nonpigmented bilateral micronodular hyperplasia thought to have resulted from longstanding Cushing disease [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Iatrogenic or factitious
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iatrogenic or factitious Cushing syndrome is usually caused by administration of excessive amounts of a synthetic glucocorticoid [
         <a href="#rid63">
          63
         </a>
         ]. It is only rarely caused by ACTH administration. (See
         <a class="local">
          'ACTH-dependent Cushing syndrome'
         </a>
         above.)
        </p>
        <p>
         Exogenous glucocorticoids inhibit CRH and ACTH secretion, causing bilateral adrenocortical atrophy. Plasma ACTH, serum and salivary cortisol concentrations, and urinary cortisol excretion (unless cortisol is the steroid administered) are all low [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         The most common cause of iatrogenic Cushing syndrome is ingestion of prescribed
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , usually for treatment of a nonendocrine disease (see
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids", section on 'Metabolic and endocrine effects'
         </a>
         ). However, Cushing syndrome also can be caused by other oral, injected, topical, and inhaled glucocorticoids [
         <a href="#rid64">
          64-66
         </a>
         ] and by
         <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">
          megestrol acetate
         </a>
         or high-dose medroxyprogesterone, progestins with some intrinsic glucocorticoid activity [
         <a href="#rid67">
          67
         </a>
         ]. The clearance of some inhaled steroids may be delayed by
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         , leading to Cushing syndrome [
         <a href="#rid68">
          68
         </a>
         ]. Cushing syndrome may also be caused by the use of glucocorticoid-containing creams or herbal preparations [
         <a href="#rid69">
          69,70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids", section on 'Adrenal suppression'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/173.html" rel="external">
          "Causes of secondary and tertiary adrenal insufficiency in adults", section on 'Chronic high-dose glucocorticoid therapy'
         </a>
         .)
        </p>
        <p>
         Factitious Cushing syndrome is a rare disorder (responsible for less than 1 percent of patients with Cushing syndrome) that refers to surreptitious intake of a glucocorticoid, often by patients who are close to the health professions [
         <a href="#rid63">
          63,71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2782589705">
         <span class="h2">
          Rare disorders
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ectopic cortisol secretion
         </strong>
         – Rare cases of ectopic cortisol production from ovarian tumors that led to ACTH-independent Cushing syndrome have been described [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Normocortisolemic Cushing syndrome
         </strong>
         –
         <strong>
         </strong>
         Two patients have been described who had signs of Cushing syndrome but had normal or low cortisol secretion. One was a 54-year-old man with centripetal obesity, moon facies, and type 2 diabetes but no other clinical abnormalities [
         <a href="#rid73">
          73
         </a>
         ]. He had low serum cortisol and undetectable plasma ACTH concentrations and failed to respond normally to the short ACTH, insulin-induced hypoglycemia, CRH-plus-vasopressin, and
         <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">
          metyrapone
         </a>
         stimulation tests. Cortisol secretion increased markedly in response to a two-day
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         . These findings are typical of administration of exogenous synthetic glucocorticoid, which was excluded by prolonged observation. The investigators concluded that there was increased tissue sensitivity to cortisol and demonstrated increased induction of a glucocorticoid-responsive gene in the patient's fibroblasts by
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The other patient was a 10-year-old girl with centripetal obesity, moon facies, purple striae, osteopenia, vertebral compression fractures, and amenorrhea but normal linear growth [
         <a href="#rid75">
          75
         </a>
         ]. Her plasma ACTH concentrations were normal and, although she appeared on occasion to have an abnormal diurnal rhythm in serum cortisol, urinary cortisol excretion was always normal, excluding hypercortisolism. She had a variable increase in type 2 corticosteroid (glucocorticoid) receptor numbers in her peripheral lymphocytes, but these did not correlate with her clinical course. The receptor gene and its promoter usage were normal. Her condition improved when she took
         <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">
          mifepristone
         </a>
         but did not worsen when it was discontinued after 21 months at age 15.5 years. The pathogenesis of this forme fruste of Cushing syndrome is unknown.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biochemical hypercortisolism without Cushingoid features
         </strong>
         –
         <strong>
         </strong>
         Two patients with clear-cut, moderate to severe hypercortisolism but absent clinical features have been described [
         <a href="#rid76">
          76,77
         </a>
         ]. Each had impaired cortisone-to-cortisol conversion in vivo and decreased cortisol-to-cortisone metabolites, consistent with impaired 11-beta hydroxysteroid dehydrogenase type 1 activity. Increased cortisol clearance was postulated as the mechanism by which the patients were protected from tissue actions of cortisol.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15600.html" rel="external">
          "Patient education: Cushing syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2173.html" rel="external">
          "Patient education: Cushing syndrome (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/2177.html" rel="external">
          "Patient education: Cushing syndrome treatment (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1083996610">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cushing syndrome may be either corticotropin (ACTH) dependent or independent  (
         <a class="graphic graphic_table graphicRef50582" href="/z/d/graphic/50582.html" rel="external">
          table 1
         </a>
         ). Among all patients presenting with Cushing syndrome, the most common cause is iatrogenic Cushing due to exogenous administration of glucocorticoids. The second most common form overall is Cushing disease (pituitary tumoral hypersecretion of ACTH). (See
         <a class="local">
          'Iatrogenic or factitious'
         </a>
         above and
         <a class="local">
          'Cushing disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pseudo-Cushing syndrome refers to physiologic hypercortisolism that can occur in several disorders other than Cushing syndrome. Examples include severe obesity, depression, chronic strenuous activity, and alcoholism. (See
         <a class="local">
          'Pseudo-Cushing syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The causes of ACTH-dependent Cushing syndrome are associated with bilateral adrenocortical hyperplasia. Their relative frequency is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cushing disease (pituitary hypersecretion of ACTH) – 65 to 70 percent. (See
         <a class="local">
          'Cushing disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ectopic secretion of ACTH by nonpituitary tumors – 10 to 15 percent. (See
         <a class="local">
          'Ectopic ACTH syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ectopic secretion of corticotropin-releasing hormone (CRH) by nonhypothalamic tumors causing pituitary hypersecretion of ACTH – Less than 1 percent. (See
         <a class="local">
          'Ectopic CRH syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The causes and frequencies of ACTH-independent Cushing syndrome are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Iatrogenic or factitious Cushing syndrome. (See
         <a class="local">
          'Iatrogenic or factitious'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adrenocortical adenomas and carcinomas – 18 to 20 percent. (See
         <a class="local">
          'Primary adrenocortical hyperfunction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Primary pigmented nodular adrenocortical disease (PPNAD), also called bilateral adrenal micronodular hyperplasia – Less than 1 percent. (See
         <a class="local">
          'Primary pigmented nodular adrenocortical disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bilateral macronodular adrenal hyperplasia (BMAH) – Less than 1 percent. (See
         <a class="local">
          'Bilateral macronodular adrenal hyperplasia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3602359821">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. Lancet 2015; 386:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kling MA, Roy A, Doran AR, et al. Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications. J Clin Endocrinol Metab 1991; 72:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chabre O. [Cushing syndrome: Physiopathology, etiology and principles of therapy]. Presse Med 2014; 43:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findling JW, Raff H. DIAGNOSIS OF ENDOCRINE DISEASE: Differentiation of pathologic/neoplastic hypercortisolism (Cushing's syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing's syndrome). Eur J Endocrinol 2017; 176:R205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88:5593.
          </a>
         </li>
         <li class="breakAll">
          Orth DN. Ectopic hormone production. In: Endocrinology and metabolism, 2nd, Felig P, Baxter JD, Broadus AE, Frohman LA (Eds), McGraw-Hill, New York 1987. p.1692.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katznelson L, Bogan JS, Trob JR, et al. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 1998; 83:1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo YS, Isidori AM, Wat WZ, et al. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 2005; 90:4963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hellman L, Weitzman ED, Roffwarg H, et al. Cortisol is secreted episodically in Cushing's syndrome. J Clin Endocrinol Metab 1970; 30:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sederberg-Olsen P, Binder C, Kehlet H, et al. Episodic variation in plasma corticosteroids in subjects with Cushing's syndrome of differing etiology. J Clin Endocrinol Metab 1973; 36:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyar RM, Witkin M, Carruth A, Ramsey J. Circadian cortisol secretory rhythms in Cushing's disease. J Clin Endocrinol Metab 1979; 48:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu JH, Kazer RR, Rasmussen DD. Characterization of the twenty-four hour secretion patterns of adrenocorticotropin and cortisol in normal women and patients with Cushing's disease. J Clin Endocrinol Metab 1987; 64:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart PM, Penn R, Gibson R, et al. Hypothalamic abnormalities in patients with pituitary-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 1992; 36:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Berg G, Frölich M, Veldhuis JD, Roelfsema F. Combined amplification of the pulsatile and basal modes of adrenocorticotropin and cortisol secretion in patients with Cushing's disease: evidence for decreased responsiveness of the adrenal glands. J Clin Endocrinol Metab 1995; 80:3750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roelfsema F, Pincus SM, Veldhuis JD. Patients with Cushing's disease secrete adrenocorticotropin and cortisol jointly more asynchronously than healthy subjects. J Clin Endocrinol Metab 1998; 83:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LIDDLE GW, ISLAND D, RINFRET AP, FORSHAM PH. Factors enhancing the response of the human adrenal to corticotropin. Is there an adrenal growth factor? J Clin Endocrinol Metab 1954; 14:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segal BM, Drucker WD, Benovitz H, et al. Further studies of adrenal weight-maintaining activity in the plasma of patients with Cushing's disease. Am J Med 1970; 49:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hornsby PJ, Sturek M, Harris SE, Simonian MH. Serum and growth factor requirements for proliferation of human adrenocortical cells in culture: comparison with bovine adrenocortical cells. In Vitro 1983; 19:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estivariz FE, Morano MI, Carino M, et al. Adrenal regeneration in the rat is mediated by mitogenic N-terminal pro-opiomelanocortin peptides generated by changes in precursor processing in the anterior pituitary. J Endocrinol 1988; 116:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reincke M, Beuschlein F, Latronico AC, et al. Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression. Clin Endocrinol (Oxf) 1997; 46:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonini SR, Baldacchino V, Tremblay J, et al. Expression of ACTH receptor pathway genes in glucose-dependent insulinotrophic peptide (GIP)-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2006; 64:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LIDDLE GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1960; 20:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karl M, Von Wichert G, Kempter E, et al. Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab 1996; 81:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huizenga NA, de Lange P, Koper JW, et al. Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. J Clin Endocrinol Metab 1998; 83:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korbonits M, Bujalska I, Shimojo M, et al. Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. J Clin Endocrinol Metab 2001; 86:2728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilodeau S, Vallette-Kasic S, Gauthier Y, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 2006; 20:2871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vergès B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002; 87:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi Y, Werk EE Jr, Sholiton LJ. Cushing's syndrome with dual pituitary-adrenal control. Arch Intern Med 1970; 125:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke CW. Disorders of cortisol production: diagnostic and therapeutic progress. Recent Adv Endocrinol Metab 1978; 1:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aron DC, Findling JW, Fitzgerald PA, et al. Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome. Report of two cases and review of the literature. Am J Med 1981; 71:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smals AG, Pieters GF, van Haelst UJ, Kloppenborg PW. Macronodular adrenocortical hyperplasia in long-standing Cushing's disease. J Clin Endocrinol Metab 1984; 58:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke CW. Adrenocortical insufficiency. Clin Endocrinol Metab 1985; 14:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermus AR, Pieters GF, Smals AG, et al. Transition from pituitary-dependent to adrenal-dependent Cushing's syndrome. N Engl J Med 1988; 318:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strott CA, Nugent CA, Tyler FH. Cushing's syndrome caused by bronchial adenomas. Am J Med 1968; 44:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malchoff CD, Orth DN, Abboud C, et al. Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med 1988; 84:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Keyzer Y, Lenne F, Auzan C, et al. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J Clin Invest 1996; 97:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White A, Ray DW, Talbot A, et al. Cushing's syndrome due to phaeochromocytoma secreting the precursors of adrenocorticotropin. J Clin Endocrinol Metab 2000; 85:4771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           More J, Young J, Reznik Y, et al. Ectopic ACTH syndrome in children and adolescents. J Clin Endocrinol Metab 2011; 96:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90:4955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neary NM, Lopez-Chavez A, Abel BS, et al. Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years. J Clin Endocrinol Metab 2012; 97:2223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arioglu E, Doppman J, Gomes M, et al. Cushing's syndrome caused by corticotropin secretion by pulmonary tumorlets. N Engl J Med 1998; 339:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascual-Le Tallec L, Dulmet E, Bertagna X, de Keyzer Y. Identification of genes associated with the corticotroph phenotype in bronchial carcinoid tumors. J Clin Endocrinol Metab 2002; 87:5015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picon A, Bertagna X, de Keyzer Y. Analysis of the human proopiomelanocortin gene promoter in a small cell lung carcinoma cell line reveals an unusual role for E2F transcription factors. Oncogene 1999; 18:2627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Araki T, Tone Y, Yamamoto M, et al. Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease. J Clin Endocrinol Metab 2021; 106:e3346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carey RM, Varma SK, Drake CR Jr, et al. Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study. N Engl J Med 1984; 311:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schteingart DE, Lloyd RV, Akil H, et al. Cushing's syndrome secondary to ectopic corticotropin-releasing hormone-adrenocorticotropin secretion. J Clin Endocrinol Metab 1986; 63:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zorate A, Kovacs K, Flores M, et al. ACTH and CRF-producing bronchial carcinoid associated with Cushing's syndrome. Clin Endocrinol 1986; 24:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jessop DS, Cunnah D, Millar JG, et al. A phaeochromocytoma presenting with Cushing's syndrome associated with increased concentrations of circulating corticotrophin-releasing factor. J Endocrinol 1987; 113:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien T, Young WF Jr, Davila DG, et al. Cushing's syndrome associated with ectopic production of corticotrophin-releasing hormone, corticotrophin and vasopressin by a phaeochromocytoma. Clin Endocrinol (Oxf) 1992; 37:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orth DN. Corticotropin-releasing hormone in humans. Endocr Rev 1992; 13:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001; 22:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakai Y, Yanase T, Takayanagi R, et al. High expression of cytochrome b5 in adrenocortical adenomas from patients with Cushing's syndrome associated with high secretion of adrenal androgens. J Clin Endocrinol Metab 1993; 76:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beuschlein F, Schulze E, Mora P, et al. Steroid 21-hydroxylase mutations and 21-hydroxylase messenger ribonucleic acid expression in human adrenocortical tumors. J Clin Endocrinol Metab 1998; 83:2585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011; 96:3775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aupetit-Faisant B, Battaglia C, Zenatti M, et al. Hypoaldosteronism accompanied by normal or elevated mineralocorticosteroid pathway steroid: a marker of adrenal carcinoma. J Clin Endocrinol Metab 1993; 76:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsen JL, Cathey WJ, Odell WD. Primary adrenocortical nodular dysplasia, a distinct subtype of Cushing's syndrome. Case report and review of the literature. Am J Med 1986; 80:976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carney JA, Young WF Jr. Primary pigmented nodular adrenocortical disease and its associated conditions. Endocrinologist 1992; 2:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Louiset E, Duparc C, Young J, et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med 2013; 369:2115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hocher B, Bähr V, Dorfmüller S, Oelkers W. Hypercortisolism with non-pigmented micronodular adrenal hyperplasia: transition from pituitary-dependent to adrenal-dependent Cushing's syndrome. Acta Endocrinol (Copenh) 1993; 128:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iino K, Sasano H, Nagura H, et al. Adrenal adenoma with bilateral adrenocortical nodular change in a patient with Cushing's syndrome. Clin Endocrinol (Oxf) 1997; 47:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quddusi S, Browne P, Toivola B, Hirsch IB. Cushing syndrome due to surreptitious glucocorticoid administration. Arch Intern Med 1998; 158:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber SL. Cushing'S syndrome attributable to topical use of lotrisone. Endocr Pract 1997; 3:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nutting CM, Page SR. Iatrogenic Cushing's syndrome due to nasal betamethasone: a problem not to be sniffed at! Postgrad Med J 1995; 71:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes JM, Hichens M, Booze GW, Thorner MO. Cushing's syndrome from the therapeutic use of intramuscular dexamethasone acetate. Arch Intern Med 1986; 146:1848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann M, Koller E, Murgo A, et al. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997; 157:1651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samaras K, Pett S, Gowers A, et al. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90:4394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olumide YM, Akinkugbe AO, Altraide D, et al. Complications of chronic use of skin lightening cosmetics. Int J Dermatol 2008; 47:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oldenburg-Ligtenberg PC, van der Westerlaken MM. A woman with Cushing's syndrome after use of an Indonesian herb: a case report. Neth J Med 2007; 65:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cizza G, Nieman LK, Doppman JL, et al. Factitious Cushing syndrome. J Clin Endocrinol Metab 1996; 81:3573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marieb NJ, Spangler S, Kashgarian M, et al. Cushing's syndrome secondary to ectopic cortisol production by an ovarian carcinoma. J Clin Endocrinol Metab 1983; 57:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iida S, Nakamura Y, Fujii H, et al. A patient with hypocortisolism and Cushing's syndrome-like manifestations: cortisol hyperreactive syndrome. J Clin Endocrinol Metab 1990; 70:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujii H, Iida S, Gomi M, et al. Augmented induction by dexamethasone of metallothionein IIa messenger ribonucleic acid in fibroblasts from a patient with cortisol hyperreactive syndrome. J Clin Endocrinol Metab 1993; 76:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newfield RS, Kalaitzoglou G, Licholai T, et al. Normocortisolemic Cushing's syndrome initially presenting with increased glucocorticoid receptor numbers. J Clin Endocrinol Metab 2000; 85:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomlinson JW, Draper N, Mackie J, et al. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab 2002; 87:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arai H, Kobayashi N, Nakatsuru Y, et al. A case of cortisol producing adrenal adenoma without phenotype of Cushing's syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity. Endocr J 2008; 55:709.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 125 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26004339" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1846869" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24656295" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : [Cushing syndrome: Physiopathology, etiology and principles of therapy].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18334580" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28179447" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : DIAGNOSIS OF ENDOCRINE DISEASE: Differentiation of pathologic/neoplastic hypercortisolism (Cushing's syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing's syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14671138" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Diagnosis and complications of Cushing's syndrome: a consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14671138" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Diagnosis and complications of Cushing's syndrome: a consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9589666" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15886242" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4315484" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cortisol is secreted episodically in Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4698248" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Episodic variation in plasma corticosteroids in subjects with Cushing's syndrome of differing etiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/219007" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Circadian cortisol secretory rhythms in Cushing's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3031116" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Characterization of the twenty-four hour secretion patterns of adrenocorticotropin and cortisol in normal women and patients with Cushing's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1319858" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hypothalamic abnormalities in patients with pituitary-dependent Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8530629" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Combined amplification of the pulsatile and basal modes of adrenocorticotropin and cortisol secretion in patients with Cushing's disease: evidence for decreased responsiveness of the adrenal glands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9467594" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Patients with Cushing's disease secrete adrenocorticotropin and cortisol jointly more asynchronously than healthy subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13183979" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Factors enhancing the response of the human adrenal to corticotropin. Is there an adrenal growth factor?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4317271" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Further studies of adrenal weight-maintaining activity in the plasma of patients with Cushing's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6654379" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Serum and growth factor requirements for proliferation of human adrenocortical cells in culture: comparison with bovine adrenocortical cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2832502" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Adrenal regeneration in the rat is mediated by mitogenic N-terminal pro-opiomelanocortin peptides generated by changes in precursor processing in the anterior pituitary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9231058" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16402925" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Expression of ACTH receptor pathway genes in glucose-dependent insulinotrophic peptide (GIP)-dependent Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13761950" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8550738" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9506748" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11397878" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17043312" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11836268" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11739416" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Guidelines for diagnosis and therapy of MEN type 1 and type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4378134" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cushing's syndrome with dual pituitary-adrenal control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Disorders of cortisol production: diagnostic and therapeutic progress
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6266251" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome. Report of two cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6315761" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Macronodular adrenocortical hyperplasia in long-standing Cushing's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3002680" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Adrenocortical insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2832758" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Transition from pituitary-dependent to adrenal-dependent Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4294885" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cushing's syndrome caused by bronchial adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2840823" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8636444" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11134141" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cushing's syndrome due to phaeochromocytoma secreting the precursors of adrenocorticotropin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21346064" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Ectopic ACTH syndrome in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15914534" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22508705" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9744972" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cushing's syndrome caused by corticotropin secretion by pulmonary tumorlets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12414866" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Identification of genes associated with the corticotroph phenotype in bronchial carcinoid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10353606" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Analysis of the human proopiomelanocortin gene promoter in a small cell lung carcinoma cell line reveals an unusual role for E2F transcription factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34061962" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6328303" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3525603" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Cushing's syndrome secondary to ectopic corticotropin-releasing hormone-adrenocorticotropin secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : ACTH and CRF-producing bronchial carcinoid associated with Cushing's syndrome
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3035046" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A phaeochromocytoma presenting with Cushing's syndrome associated with increased concentrations of circulating corticotrophin-releasing factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1283118" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cushing's syndrome associated with ectopic production of corticotrophin-releasing hormone, corticotrophin and vasopressin by a phaeochromocytoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1319897" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Corticotropin-releasing hormone in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11159817" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8496319" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : High expression of cytochrome b5 in adrenocortical adenomas from patients with Cushing's syndrome associated with high secretion of adrenal androgens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9661649" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Steroid 21-hydroxylase mutations and 21-hydroxylase messenger ribonucleic acid expression in human adrenocortical tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21917861" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8421100" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Hypoaldosteronism accompanied by normal or elevated mineralocorticosteroid pathway steroid: a marker of adrenal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3010718" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Primary adrenocortical nodular dysplasia, a distinct subtype of Cushing's syndrome. Case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Primary pigmented nodular adrenocortical disease and its associated conditions
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24283225" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8383903" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Hypercortisolism with non-pigmented micronodular adrenal hyperplasia: transition from pituitary-dependent to adrenal-dependent Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9373462" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Adrenal adenoma with bilateral adrenocortical nodular change in a patient with Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9472211" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cushing syndrome due to surreptitious glucocorticoid administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15251475" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cushing'S syndrome attributable to topical use of lotrisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7784285" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Iatrogenic Cushing's syndrome due to nasal betamethasone: a problem not to be sniffed at!
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3753129" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Cushing's syndrome from the therapeutic use of intramuscular dexamethasone acetate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9250225" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15755851" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18377596" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Complications of chronic use of skin lightening cosmetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17452765" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A woman with Cushing's syndrome after use of an Indonesian herb: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8855803" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Factitious Cushing syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6309883" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cushing's syndrome secondary to ectopic cortisol production by an ovarian carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2155254" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A patient with hypocortisolism and Cushing's syndrome-like manifestations: cortisol hyperreactive syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8432788" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Augmented induction by dexamethasone of metallothionein IIa messenger ribonucleic acid in fibroblasts from a patient with cortisol hyperreactive syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10634357" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Normocortisolemic Cushing's syndrome initially presenting with increased glucocorticoid receptor numbers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11788623" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18493111" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A case of cortisol producing adrenal adenoma without phenotype of Cushing's syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
